Clinical trial · Interventional
HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients
High-Flow Nasal Oxygenation Combined With Nasopharyngeal Airway Reduces The Incidence Of Hypoxia During Gastrointestinal Endoscopy Sedated With Propofol In Obese Patients: A Prospective, Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Obesity is associated with adverse airway events including desaturation during deep sedation. Previous studies have suggested that high-flow nasal oxygenation may be superior to regular (low-flow) nasal cannula for prevention of hypoxia during Sedated Gastrointestinal Endoscopy in non-obesity patients. The prerequisite of high-flow nasal oxygenation is keeping airway patency. Our pervious study demonstrated that nasopharyngeal airway has the similar efficacy of jaw-lift. In present study we aimed to determine whether high-flow nasal oxygenation combined with nasopharyngeal airway could reduce the incidence of hypoxia during Sedated Gastrointestinal Endoscopy in obese patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastric Ulcer | — | UNRESOLVED | — |
| Intestinal Cancer | Malignant Intestinal Neoplasm | ALIAS | 0.90 |
| Intestinal Polyps | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| High-flow nasal oxygenation combined with nasopharyngeal airway | Device | — | UNRESOLVED |
| Regular nasal cannula combined with nasopharyngeal airway | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- High-flow nasal oxygenation combined with nasopharyngeal airway
- description
- High-flow nasal oxygenation combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
- interventionNames
- Device: High-flow nasal oxygenation combined with nasopharyngeal airway
- type
- ACTIVE_COMPARATOR
- label
- Regular nasal cannula combined with nasopharyngeal airway
- description
- Regular nasal cannula combined with nasopharyngeal airway was used in obese patients who are scheduled to undergo gastrointestinal endoscopy procedures sedated with propofol.
- interventionNames
- Device: Regular nasal cannula combined with nasopharyngeal airway
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients receiving selective combined upper intestinal and lower intestinal endoscopy procedure under deep sedation. 2. Age ranging from 19 to 80, both male and female 3. Obese patients，BMI ≥ 28kg/m\^2 4. ASA I\~III 5. Patients should clearly understand and voluntarily participate in the study, with signed informed consent. Exclusion Criteria: 1. Patients with acute respiratory infection in the last 2 weeks 2. Patients with nasal congestion, epistaxis, recent nasal trauma, recent nasal surgery 3. hypoxia, defined as oxygen saturation measured by pulse oximetry (SpO2) ≤ 95% before preoxygenation. 4. Common advanced gastrointestinal endoscopy procedures meeting eligibility criteria included cholangiopancreatography, endoscopic ultrasound procedures, endoscopic mucosal resection and endoscopic retrograde cholangiopancreatography (ERCP) procedures. 5. coagulation disorders or platelets \< 100\*10\^9/L 6. Have serious heart diseases such as severe arrhythmia, heart failure, Adams Stokes Disease, unstable angina pectoris, myocardial infarction in the last 6 months, history of tachycardia / bradycardia requiring medical treatment, third degree atrioventricular block or QTC interval ≥ 450ms (corrected according to fridericia's formula), or exercise tolerance \< 4mets 7. Allergy to eggs, soy products, opioids and other drugs, propofol, etc. 8. Participated in other clinical trials as a subject within 3 months 9. Patients with brain injury, possible convulsion, myoclonus, intracranial hypertension, cerebral aneurysm, cerebrovascular accident history, schizophrenia, intellectual disability, mania, psychosis, long-term use of psychotropic drugs, drug addiction, cognitive dysfunction history, etc. 10. Emergency procedure 11. Pregnant or breast-feeding women 12. Patients having procedures with planned tracheal intubation or laryngeal mask 13. Investigator considers the patients are inappropriate to participate in this trial
References
Publications (0)
Data not yet available